Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY and JULIE MAK

Haemonetics Stock Near Buy Zone With EPS Due

With its next earnings report scheduled for around Aug. 10, Haemonetics stock is trading about 10% shy of a 75.44 buy point. The current formation is a first-stage consolidation.

Understand that it's risky to buy any stock just before it reports. You can reduce your exposure by waiting to see how the company reports and how the market reacts.

Looking For Winning Stocks? Try This Simple Routine

Earnings grew 41% last quarter, up from 4% in the prior report. Revenue also increased, from 8% to 18%.

Consensus analyst estimates call for earnings growth of 2% for the quarter, and a 6% gain for the full year.

Haemonetics stock has a 96 Composite Rating and holds the No. 2 rank among its peers in the Medical-Systems/Equipment industry group. Haemonetics is the top-ranked stock within the group.

Note: Dates for earnings reports are subject to change. Check the company's website for any updates.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.